PDCD1 and cancer: Blockade of the PD-1/PD-L1 axis with the anti-PD-1 antibodies pembrolizumab and nivolumab as well as the anti-PD-L1 antibodies atelizumab, avelumab and durvalumab has been approved for the treatment of various cancers.